In this issue:
6-week dosing of natalizumab vs 4-week dosing in RRMS
Disease course of early and late onset paediatric MS
Relationship between white matter lesions and gray matter atrophy in MS
Menopause does not modify disability trajectories in women with CIS and MS
Incidence and risk of cancer among MS patients
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment for relapsing MS
Impact of vaccination on SARSCoV-2 infections among MS patients taking DMTs
Anti-SARS-CoV-2 monoclonal antibodies for active COVID-19 in MS
Impact of smoking cessation on MS progression
Autologous HSCT in 507 MS patients
Please login below to download this issue (PDF)